RESUMEN

There is controversy about patient outcomes and pathological parameters of prognostic significance in patients with stage II or stage III ovarian serous borderline tumors. Forty-nine cases of stage II and III ovarian serous borderline tumors were identified on review of the medical records at Vancouver Hospital and British Columbia Cancer Agency for the period from 1979 to 1996. Pathological features assessed included presence of micropapillary architecture, tumor cell DNA content (ploidy), and characteristics of the extraovarian implants, including invasiveness and mitotic activity. Clinical follow-up information (3-17 years of follow-up) was obtained for 48 patients. Fifteen patients had stage II tumors and 34 had stage III tumors. Fourteen patients experienced tumor recurrence 1 to 8 (mean 3.5) years after presentation and of these, six patients died of disease (2, 3, 4, 7, 10, and 11 years after presentation). Patients with gross residual disease, as assessed by the surgeon, more frequently experienced a recurrence compared with patients without gross residual disease, but this difference did not reach statistical significance (0.05

Asunto(s)

Cistadenocarcinoma Seroso/patología , Recurrencia Local de Neoplasia , Neoplasias Ováricas/patología , Terapia Combinada , Cistadenocarcinoma Seroso/terapia , Femenino , Procedimientos Quirúrgicos Ginecológicos/métodos , Humanos , Siembra Neoplásica , Estadificación de Neoplasias , Neoplasias Ováricas/terapia , Pronóstico , Estudios Retrospectivos , Análisis de Supervivencia